General Information of Drug (ID: DM4LKFO)

Drug Name
NELOTANSERIN Drug Info
Synonyms
NELOTANSERIN; 839713-36-9; UNII-4ZA73QEW2P; 4ZA73QEW2P; CHEMBL598172; APD125; APD-125; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea; 1-[3-(4-BROMO-1-METHYL-1H-PYRAZOL-5-YL)-4-METHOXYPHENYL]-3-(2,4-DIFLUOROPHENYL)UREA; N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-N'-(2,4-difluorophenyl)-Urea; Nelotanserin [USAN:INN]; Nelotanserin (USAN/INN); SCHEMBL2345325; APD 125; DTXSID40232868; COSPVUFTLGQDQL-UHFFFAOYSA-N; BCP24992; ZINC38239930; BDBM50324541; AKOS027255058; DB12555
Indication
Disease Entry ICD 11 Status REF
Lewy body dementia 6D82 Phase 2 [1]
Sleep-wake disorder 7A00-7B2Z Discontinued in Phase 2 [2]
Cross-matching ID
PubChem CID
11683556
CAS Number
CAS 839713-36-9
TTD Drug ID
DM4LKFO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [4]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [5]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [6]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [7]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [8]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [9]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [10]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [11]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [12]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Modulator [3]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021795)
3 Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia.J Pharmacol Exp Ther.2010 Jan;332(1):281-90.
4 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
5 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
6 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
7 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
8 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
9 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
11 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
12 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
13 Clinical pipeline report, company report or official report of Lundbeck.